Department of Pharmacology, GMERS Medical College, Gotri, Vadodara, Gujarat, 390021, India.
Eur J Clin Pharmacol. 2019 Sep;75(9):1293-1307. doi: 10.1007/s00228-019-02702-4. Epub 2019 Jun 11.
To estimate the prevalence of mortality among patients that develop adverse drug reactions during hospitalisation (ADR), to examine heterogeneity through subgroup analysis and to identify system-organ class (SOC) and their causative drugs.
Two investigators searched PubMed, Google Scholar and related bibliography for studies reporting ADR-related mortality data. The primary outcome was to compute overall prevalence of fatal ADR (95% CI) using double arcsine method. We explored the heterogeneity (I) in its estimation based on study design, study population and data collection methods. The secondary outcomes were the pattern of fatal reactions and their causative drugs. PROSPERO register number-CRD42018090331.
Out of 349 full text assessed, 48 studies satisfying the selection criteria were included. The fatal ADR prevalence was 0.11% (95% CI 0.06-0.18%; I = 93%). The fatal ADR prevalence ranged from 0.03% (I = 0%) in all ages to 0.27% (I = 90%) in elderly population studies. Elderly studies varied for all study characteristics. Among study wards, a higher trend of prevalence was observed in 'internal medicine and ICU' (0.46%, I = 51%) and 'neonatal/paediatric ward and ICU' (0.34%, I = 58%) studies. The commonly involved SOC were 'gastrointestinal disorders' (28.79%), 'blood and lymphatic system disorders' (19.69%) and 'renal and urinary disorders' (13.64%). Most commonly observed causative drug-fatal ADR pairs were antithrombotics and nonsteroidal anti-inflammatory drugs induced gastrointestinal bleeding, and antineoplastic agents induced cytopenia.
ADR is an important cause of mortality. Age groups and study wards have important influence on prevalence of fatal ADR and its heterogeneity across studies. Few class drugs contribute to sizable proportion of ADR-related mortality.
评估住院期间发生药物不良反应(ADR)的患者的死亡率,通过亚组分析评估异质性,并确定系统器官类别(SOC)及其致病药物。
两名调查员搜索了 PubMed、Google Scholar 和相关文献,以查找报告 ADR 相关死亡率数据的研究。主要结局是使用双反正弦法计算致命 ADR 的总体患病率(95%CI)。我们根据研究设计、研究人群和数据收集方法探讨了其估计的异质性(I)。次要结局是致命反应的模式及其致病药物。PROSPERO 注册号-CRD42018090331。
在评估的 349 篇全文中,有 48 篇符合选择标准的研究被纳入。致命 ADR 的患病率为 0.11%(95%CI 0.06-0.18%;I=93%)。致命 ADR 的患病率从所有年龄段的 0.03%(I=0%)到老年人群研究中的 0.27%(I=90%)不等。老年人群的研究在所有研究特征上均存在差异。在研究病房中,“内科和 ICU”(0.46%,I=51%)和“新生儿/儿科病房和 ICU”(0.34%,I=58%)的研究中观察到更高的患病率趋势。常见的 SOC 包括“胃肠道疾病”(28.79%)、“血液和淋巴系统疾病”(19.69%)和“肾脏和泌尿系统疾病”(13.64%)。最常见的观察到的致病药物-致命 ADR 对是抗血栓药物和非甾体抗炎药引起的胃肠道出血,以及抗肿瘤药物引起的细胞减少症。
ADR 是导致死亡的一个重要原因。年龄组和研究病房对致命 ADR 的患病率及其在研究之间的异质性有重要影响。少数类别药物对与 ADR 相关的死亡率有相当大的贡献。